General Anesthesia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for general anesthesia. 101 active patents protecting 5 drugs from 5+ originators. First major cliff: 2039. Daily refresh.

5
Approved drugs
101
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in General Anesthesia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson (Janssen Pharmaceutica) 68 patents Yonsei University 18 patents Bristol-Myers Squibb 8 patents Generic (originally Roche) 6 patents Merck & Co. 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating general anesthesia. Each bar = one year. Y-axis scaled to peak year (54 patents).

1
26
54
27
9
28
1
29
15
30
1
31
8
32
1
33
1
35
2
36
7
38
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25
Glycopyrrolate Yonsei University 18 53 — 2026-08-16
Acetadote
Acetylcysteine
 Bristol-Myers Squibb 8 64 — 2031-07-21
Versed
midazolam
 Generic (originally Roche) 6 61 — 2028-01-18
Rocuronium
Rocuronium Bromide
 Merck & Co. 1 55 — 2039-07-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8217033 Versed method of use 75 2028-01-18
9687495 Versed method of use 75 2028-01-18
9289432 Versed method of use 75 2028-01-18
10940110 Glycopyrrolate method of use 75 2029-02-26
8722738 Acetadote method of use 73 2032-04-06
11278683 Glycopyrrolate formulation 68 2026-08-16
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
10966990 Versed formulation 42 2038-06-20
10966990 Versed formulation 42 2038-06-20
10688518 Glycopyrrolate formulation 42 2036-11-12

Related